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Abstract
Ideal nanoparticle (NP)-based drug and vaccine delivery vectors should be free of inherent 
cytotoxic or immunostimulatory properties. Therefore, determining baseline immune responses to 
nanomaterials is of utmost importance when designing human therapeutics. We characterized the 
response of human immune cells to hydrogel NPs fabricated using Particle Replication in Non-
wetting Templates (PRINT) technology. We found preferential NP uptake by primary CD14+ 
monocytes, which was significantly reduced upon PEGylation of the NP surface. Multiplex 
cytokine analysis of NP treated primary human peripheral blood mononuclear cells (hu-PBMC) 
suggests that PRINT based hydrogel NPs do not evoke significant inflammatory responses nor do 
they induce cytotoxicity or complement activation. We furthered these studies using an in vivo 
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humanized mouse model and similarly found preferential NP uptake by human CD14+ monocytes 
without systemic inflammatory cytokine responses. These studies suggest that PRINT hydrogel 
particles form a desirable platform for vaccine and drug delivery as they neither induce 
inflammation nor toxicity.
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Introduction
Biocompatible particles at the nano/micron scale are emerging tools for biological 
programming with the capacity to induce specific cellular responses in a variety of disease 
contexts. This has been demonstrated using mouse models of anti-microbial vaccines, cancer 
immunotherapy, tolerance induction during autoimmunity and siRNA-mediated gene 
knockdown (1–9). Concomitant with advances in nanotechnology there is a widespread 
appreciation for ensuring nanoparticle safety and biocompatibility with special consideration 
for adverse immune responses (10, 11). Therefore, determining how novel drug and vaccine 
platforms interact with the human immune system is of critical importance.
The particle replication in nonwetting templates (PRINT) process uses soft lithography to 
generate monodisperse NPs with highly defined size, shape, charge and composition (12, 
13). PRINT particles can be engineered to carry a variety of payloads including 
chemotherapeutics, imaging agents, antigens and adjuvants (14, 15). Additionally, the 
particle surface can be modified to facilitate antibody or cellular receptor based targeting 
and the addition of short PEG chains (PEGylation) can reduce NP clearance in mice by 
preventing serum protein binding and subsequent recognition by phagocytic cells (16, 17).
The nanotechnology field is continually expanding and encompasses a variety of materials, 
some of which are reported to induce toxicity and/or adverse immune responses, including 
metals, metal oxides, carbon-nanotubes, liposomes and some polymer based particles (10, 
11, 18). A drawback of many therapeutic platforms is the inadvertent induction of host 
immune responses, which can lead to rapid clearance of the therapeutic and/or be deleterious 
to host. An additional consideration is the heterogeneity amongst immune responses within 
the human population. Our recent report showed that macrophages from the blood of healthy 
donors have differing abilities to ingest NPs that correlated with the M1/M2 activation status 
of the macrophage, with M2-like cells taking up more NPs (19). We found the same results 
using various inbred mouse strains with known skewing toward M1 or M2-like phenotypes, 
indicating that responses to nanomaterials in conventional mouse strains can vary greatly 
depending on their immunological makeup. More complexity arises when trying to 
extrapolate results from rodent model systems to therapeutic human applications and 
suggests that a “one-size-fits-all” approach to nanoscale clinical intervention is too 
simplistic a model. Furthermore, the fabrication process, choice of material, particle 
dimensions, route of delivery and dose may differentially affect immune responses. For 
example, some NP formulations have toxic effects on host cells by inducing cell death 
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through oxidative stress, whereas other particulate compositions of polystyrene and PLGA 
are sufficient to activate innate immune responses, such as the NLRP3 inflammasome (20, 
21). Therefore, a critical first step in development of novel vaccine and drug delivery 
platforms is to test their baseline compatibility with the human immune system.
One major consideration when developing particulate therapeutics is the potential for 
activating the NLRP3 inflammasome present in phagocytic cells (22). Inflammasomes are 
activated by two signals; signal one (also called priming) results in intracellular 
accumulation of inflammasome subunits and the pro-inflammatory cytokines IL-1β and 
IL-18. Signal two triggers inflammasome activation and subsequent release of mature IL-1β 
and IL-18, which rapidly recruit and activate inflammatory cells. If uncontrolled this can 
lead to systemic inflammation followed by organ failure and even death (23)(24, 25). It is 
known that particulate irritants such as alum, silica and asbestos are potent activators of the 
inflammasome and recent work has suggested that particles comprised of titanium oxide, 
silver, PLG and carbon can also trigger the NLRP3 inflammasome (21, 22, 26–31). The 
adverse effects of nanotherapeutics depends on many factors, including particle geometry, 
method of fabrication, dose/route of administration and the tissues/cell types assessed as 
evidenced by the contrasting results regarding nanoparticle triggering of the NLRP3 
inflammasome (21, 32–34). In addition, many studies of particle uptake and toxicity are 
carried out exclusively in cell lines, most often murinederived, which may not reflect 
responses by primary human cells (11). The studies in this manuscript test the interaction of 
human immune cells with PRINT fabricated hydrogel particles using primary human 
peripheral blood and an in vivo humanized mouse model.
Materials and Methods
Particle Materials
Poly(ethylene glycol) diacrylate (Mn 700) (PEG700DA), 2-aminoetheyl methacrylate 
hydrochloride (AEM), and Diphenyl (2,4,6-trimethylbenzoyl)-phosphine oxide (TPO) were 
from Sigma-Aldrich. Tetraethylene glycol monoacrylate (HP4A) was synthesized in-house 
as previously described (35). Thermo Scientific maleimide-terminated Dylight 650 and 
Dylight 488, PTFE syringe filters (13mm membrane, 0.220 µm pore size), 
dimethylformamide (DMF), triethanolamine (TEA), pyridine, sterile water, borate buffer 
(pH 8.6), Dulbecco’s 1× phosphate buffered saline (DPBS) (pH 7.4), acetic anhydride and 
methanol were obtained from Fisher Scientific. Methoxy-PEG(5k)-succinimidyl carboxy 
methyl ester (mPEG5k-SCM) was purchased from Creative PEGWorks. Conventional filters 
(2 µm) were purchased from Agilent and polyvinyl alcohol (Mw 2000) (PVOH) was 
purchased from Acros Organics. Liquidia Technologies kindly provided the 80 nm × 320 
nm PRINT molds used in these studies.
Fabrication of PRINT HP4A particles
The process of fabricating hydrogel particles has been described previously (12). Briefly, the 
pre-particle solution of 67.5 wt% HP4A, 20 wt% AEM (functional monomer), 10 wt% 
PEG700DA (crosslinker), 1 wt% TPO (photo initiator) and 1.5 wt% Dylight 650 or Dylight 
488 maleimide was dissolved at 3.5 wt% in methanol and drawn as a thin film using a #3 
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Mayer rod (R.D. Specialties) onto a roll of corona treated PET using an in-house custom-
made roll-to-roll lab line (Liquidia Technologies). The delivery sheet was laminated to the 
patterned side of the mold, followed by delamination at the nip. Particles were cured by 
passing the filled mold through a UV-LED and a PVOH harvesting sheet was hot laminated 
to the filled molds of 80×320 nm rods. Particles were removed from the mold at room temp 
by splitting the PVOH harvesting sheet from the mold and harvested using 1 mL of water 
per 5 ft of harvesting sheet. Particle suspensions were passed through a 2 µm filter (Agilent) 
to remove large particulates. Excess PVOH was removed by centrifugation of NPs and 4 
washes with sterile water prior to final resuspension in water.
PEGylation of 80×320 nm HP4A NPs
Free primary amine groups on the HP4A particles were used as chemical handles to react 
with a methoxy-PEG5K-SCM. Purified 80×320 nm hydrogel particles were exchanged from 
water to DMF at (1 mg/mL) and were reacted with TEA (100 µL) for 10 min at room 
temperature on a shaker plate at 1400 rpm. 14 mg of methoxy-PEG5K-SCM was dissolved 
in DMF and added to the reaction mixture, shaken overnight and then quenched with borate 
buffer (100 µL). The nanoparticle solution was then centrifuged (21,000 RCF; 15 minutes) 
and washed 5 times with DMF. Following PEGylation, particles were acetylated with acetic 
anhydride to quench any unreacted amines and washed once in DMF, once in borate buffer 
and four times in sterile water.
Print Particle Characterization
Stock particle concentrations were determined using thermogravimetric analysis (TGA; TA 
Instruments Q5000 TGA). The stock particle solution (20 µL) was pipetted into a tared 
aluminum sample pan. The sample was heated at 30°C/min to 130°C and held at this 
temperature for 10 minutes followed by cooling at 30°C/min to 30°C and held for 2 minutes. 
To account for the mass of any stabilizer remaining in each sample, TGA was performed on 
a 20 µL aliquot of supernatant from a centrifuged sample of the stock particle solution. A 
Zetasizer Nano ZS (Malvern Instruments, Ltd.) was used to measure particle size and zeta 
potential by dynamic light scattering (DLS). NPs were prepared for scanning electron 
microscopy (SEM) by coating with 1.5 nm of gold-palladium alloy using a Cressington 108 
auto sputter coater and imaged using a Hitachi S-4700 scanning electron microscope.
Particle Uptake and Cytokine Secretion by THP-1cells
THP-1 monocytes were seeded at 2×105 cells/well in 96 well plates and incubated with 
varying doses of NPs for 24 hours or with 10–20 ng/ml LPS (O111:B4 standard preparation, 
Invivogen) and/or 20 µm nigericin (Invivogen) for the final 40 mins as positive controls for 
cytokine production. Cell supernatants were collected and assessed for cytokine production 
by ELISA. Cells were washed 3 times with FACS buffer and assessed for NP uptake using 
flow cytometry. All studies were prefomed using RPMI media with heat inactivated 10% 
fetal bovine serum.
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Human Peripheral Blood Mononuclear Cell (hu-PBMC) Isolation and Culture
Blood was collected from healthy donors or leukapheresed patients in accordance with the 
University of North Carolina’s Office of Human Research Ethics (IRB #12-1858 and 
#05-2860). Donors provided written informed consent and samples were anonymized and 
de-identified prior to use in the described studies. Peripheral blood mononuclear cell 
(PBMC) buffy coats were prepared using density gradient centrifugation (Lymphoprep from 
Cosmo Bio USA). Hu-PBMC were plated at 3×105 cells per well in 96 well plates using 
AIM V medium (Gibco) supplemented with 1% penicillin/streptomycin, 1% L-glutamine 
and 10% heat-inactivated ABhuman serum (Invitrogen). After 4 hours of rest, PRINT NP 
(10µg/ml) were added for 8 hours and supernatant was harvested for ELISA and cells were 
assessed by flow cytometry.
Enrichment of primary human CD14+ monocytes and NP cytotoxicity analysis
Primary human CD14+ monocytes were enriched from buffy coat using Dynabeads® 
Untouched™ Human Monocytes Kit (Invitrogen™) according to manufacturer instructions 
and purity assessed by flow cytometry (>95% pure). Cell cytotoxicity was determined using 
the luciferase based Toxilight™ bioassay (Lonza) in response to 100, 10 and 1 µg/ml NP 
concentrations for 12 and 24 hours according the manufacturer’s instructions. ToxiLight™ 
100% lysis reagent was used as positive control for the assay. Cell viability analysis using 
MTT (Life Technologies) was performed on NP treated human peripheral blood buffy coat 
cells by adding 0.5 mg/ml MTT for 2hr at 37°C followed by formazan solubilization 
overnight using 5% SDS and 5 mM HCl. Plates were assayed for 550 nm absorbance and a 
reference wavelength of 690 with values plotted after subtraction of background signal. UV 
irradiated cells were used as a positive control for cell death in MTT assays.
Analysis of Cytokine Production
Human TNFα, IL-6 and IL-1β secretion by THP-1 cells were analyzed using BD-OPtiea 
ELISA kits (BD Biosciences) according to the manufacturer’s instructions. Cytokine 
production by primary hu-PBMC was analyzed using the human 30-Plex Panel (Life 
Technologies) on the Luminex platform.
Analysis of Complement Activation
Studies of NP mediated complement activation were performed as described with 
modifications (36). Briefly, samples containing 10 µl human plasma (non-heat inactivated) 
(Sigma-Aldrich, lot SLBH6826V), 10 µl veronal buffer with Ca2+ and Mg2+ (Complement 
Technology Inc.), 10 µl HP4A or HP4A-PEG NP in PBS (final concentration 10ug/ml) were 
incubated for 2 hr or 8 hr at 37°C. Plasma treated with PBS served as negative control and 
50 units of cobra venom factor (Complement Technology Inc.) served as positive control for 
complement activation. Following treatment, samples were boiled for 5 minutes in 1×SDS 
sample buffer containing DTT, diluted 1:400 and 12 µl was fractionated on a 4%–10% Bis/
Tris gel (Invitrogen) followed by transfer to PVDF membrane (Millipore). Blots were 
probed with polyclonal goat anti-human C3 (Complement Technology Inc.) using a 1:2000 
dilution followed by probing with donkey anti-goat IgG- IRDye® 800CW (Li-Core 
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Biosciences) using a 1:20,000 dilution. Membranes were scanned using Li-Core Odyssey 
Infrared Imaging system (Li-Core Biosciences).
CD14 blockade
The anti-CD14 blocking antibody (clone M5E2 LEAF™ grade, Biolegend) and isotype 
control (MOPC-173 LEAF™ grade, Biolegend) were tested empirically for the ability to 
block the CD14 receptor. Primary hu-PBMC were pre-incubated with 50ug/ml anti-CD14 
(M5E2) or isotype control for 1 hour followed by NP treatment (10 µg/ml) for 8 hours. Cells 
were washed 3 times with FACS buffer and NP uptake was assessed by flow cytometry.
Humanized Mouse Experiments
All animal experiments were carried out humanely and followed protocols approved by the 
University of North Carolina-Chapel Hill Institutional Animal Care and Use Committee 
(IACUC). A detailed protocol for preparation of NOD.Rag1−/−Il2rg−/− (NRG) humanized 
mice has previously been published (37–40). In brief, human CD34+ cells were isolated 
from 15- to 18-week-old fetal liver tissues using a Ficoll gradient (GE Healthcare Bio-
science AB) and CD34+ MicroBead Kit from Miltenyi Biotec. One to 3 day old NRG mice 
were irradiated at 200 rad and injected intra-hepatically with 0.5–1×106 hu-CD34+ cells. 
Transplanted mice were bled 3–4 months later to assess human immune cell reconstitution 
by flow cytometry and only mice with >50% chimerism were used in these studies. 
Humanized mice were injected i.v. with 100µg of 80×320 nm hydrogel particles. Acetylated 
particles (HP4A) contained Dylight 650, while PEGylated versions of the same particle 
(HP4A-PEG) contained Dylight 488. Twenty-four hours after particle injections, mice were 
euthanized for tissue analysis by flow cytometry and quantative realtime PCR (Q-RT PCR).
Flow Cytometry
Antibodies used in hu-PBMC staining; CD3-FITC, CD19-eFluor®450, CD56-PerCP-Cy5, 
CD14-PE, CD11b-APC-Cy7, and CD11c –PE-Cy7 (eBioscience). Live cells were 
determined using the Live/Dead Aqua Fixable Dead Stain Kit (Invitrogen). Antibodies used 
for humanized mouse experiments: CD11c-FITC, CD56-FITC, CD14-PE, CD4-PE-Cy5, 
CD3-PE-Cy7, CD123-PE-Cy5, CD19-PB, CD11c-APC, CD56-APC, CD45-APC-Cy7 
(Biolegend); CD8-PE-TR, CD4-PE-TR, mouse CD45-Pacific Orange (Invitrogen). FACS 
buffer; 1×PBS (Gibco) + 2% FBS (Sigma). All data were collected using an LSRII (BD 
Biosciences) or CyAn™ (Beckman Coulter) flow cytometer and analyzed using FlowJo 
(Tree Star, Inc.).
Quantitative Real-time PCR
RNA was purified from spleens of humanized mice using the RNeasy Plus Minikit (Qiagen) 
and reverse transcribed to cDNA using M-MLV RT (Invitrogen) and oligo-dT. Human 
cytokine gene expression was assayed using KiCqStart SYBR Green primers for IL1B, IL6, 
and TNF (Sigma Aldrich). Primer sequences are as follows: IL1B Fwd – 5’-
ACAGTGGCAATGAGG ATGAC-3’, IL1B Rev – 5’-CCATGGCCACAACAACTGA-3’; 
IL6 Fwd – 5’-GGTACAT CCTCGACGGCATCT -3’, IL6 Rev –5’-
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GTGCCTCTTTGCTGCTTTCAC -3’; TNF Fwd – 5’-CTCT TCTGCCTGCTGCACTT-3’, 
TNF Rev – 5’-GGCTACAGGCTTGTCACTC-3’.
Statistical Analysis
Data were evaluated for statistical significance using Analysis of Variance (ANOVA) with 
the Bonferroni post-test using the GraphPad Prism 5 software.
Results
Characterization of monodisperse and homogenous PRINT nanoparticles
The PRINT fabrication process was used to generate rod shaped 80×320 nm hydrogel 
particles with a base component of HP4A. Aliquots of the 80×320 nm HP4A-NPs were 
modified by covalent attachment of short PEG5k chains to yield PEGylated HP4A-NP 
(HP4A-PEG). Particle uptake was tracked using fluorescent dyes (Dylight 650 or 488) that 
were covalently incorporated during particle fabrication. NPs were characterized by DLS to 
measure size, surface charge (zeta potential) and particle homogeneity using the 
polydispersity index (PDI) (Fig. 1A). All particles were of the expected size and had a 
negative surface charge ranging from −7.5 to −28.9 mV. The PDI for all nanoparticles was 
≤0.1 indicating a high level of homogeneity within each batch which was confirmed using 
SEM (Fig. 1B).
Uptake and immune responses to HP4A particles by the human THP-1 cell line
To determine how 80×320 nm HP4A particles interact with human immune cells we 
incubated the THP-1 monocyte line with fluorescently labeled NP for 24 hours and uptake 
was measured by flow cytometry. We found that HP4A-NPs were taken up in a dose 
dependent manner (20, 10, 1 µg/ml) and that PEGylation of the NP surface (HP4A-PEG) 
dramatically reduced particle uptake (Fig 2A). Supernatants from these cultures had 
undetectable levels of TNFα and IL-6 by ELISA suggesting that the HP4A based NPs do not 
elicit inflammatory cytokine responses (Fig. 2B). We further tested whether these NPs 
induced IL-1β secretion alone or as a second signal following LPS priming. We were unable 
to detect IL1-β in the supernatant of LPS primed (10 ng/ml) or unprimed THP-1 cells treated 
with NPs (20µg/ml), whereas nigericin (20 µM, 40 mins), a known activator of the 
inflammasome, induced robust IL-1β release (Fig. 2C). To determine if pre-treatment with 
HP4A-based NPs alters cytokine secretion in response to inflammatory cues we incubated 
THP-1 cells with (10 µg/ml) HP4A or HP4A-PEG NP for 16 hours followed by stimulation 
with LPS (20 ng/ml) for 4 hours for TNFα production, or LPS (20 ng/ml) for 4 hours and 
nigericin (20µM) for 40mins for IL-1β production. We detected no alteration in TNFα (Fig. 
2D) or IL-1β (Fig. 2E) secretion when cells were pre-treated HP4A-based NPs. Together, 
these data indicate that HP4A-based NP do not induce, enhance or dampen pro-
inflammatory cytokine release or inflammasome activation.
Analysis of HP4A NP uptake and toxicity studies using primary human immune cells
The above data from THP-1 cells suggests that HP4A-based NPs are immunologically inert 
and we sought to further these studies using primary human cells. Hu-PBMC were obtained 
from multiple donors and treated ex-vivo with fluorescently labeled HP4A or HP4A-PEG 
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NPs for 8 hours and analyzed for particle uptake using flow cytometry. NPs were 
exclusively detected in CD14+ monocytes, with undetectable NP uptake in B, T and NK 
cells (Fig. 3A). PEGylation of the NP surface reduced the frequency of particle uptake at the 
4 hour time point; however, by 8 hours similar percentages of cells had taken up detectable 
levels of NPs (Fig. 3B+C). While the frequency of NP positive cells was similar after 8 
hours, the mean fluorescence intensity (MFI) in the CD14+NP+ gate following HP4A-NP 
treatment was significantly higher than cells treated with HP4A-PEG particles at both 4 hour 
and 8 hour time points (Fig. 3D), indicating that the actual quantity of particles per cell is 
reduced with PEGylation (Fig. 3D). These data parallel those obtained in the THP-1 studies 
and are consistent with other studies showing that PEGylation reduces phagocytosis of drugs 
and nanomaterials (16, 41). Hu-PMBC were also incubated with NPs at 4°C to distinguish 
between NP uptake and cell surface binding with the expectation that minimal uptake will 
occur at low temperatures. We observed a significant difference in the MFI of un-PEGylated 
NPs compared to PEGylated particles at 4°C to allow NP binding but prevent phagocytosis 
(Fig. 3D), suggesting that part of the mechanism by which PEGylation reduces uptake may 
be through reduced NP binding to the cell surface.
Uptake of HP4A-NPs was exclusively detected in the CD14+ population of hu-PBMC (Fig. 
3A), which warranted further investigation as to whether CD14 itself was involved in NP 
uptake. CD14 has been implicated in binding a variety of ligands with differing 
characteristics including bacterial lipids (e.g. LPS), viral glycoproteins, double stranded 
viral RNA and monosodium urate crystals (42–45). To determine if HP4A-NP uptake by 
CD14+ cells requires sensing through CD14 we assessed NP uptake in the presence of a 
known CD14 blocking antibody (M2E5) (46). The optimal antibody concentration was 
empirically determined by incubating THP-1 cells for 1 hour with various doses of M2E5 
antibody or an isotype control followed by treatment with LPS and detection of TNFα 
secretion by ELISA. We found that CD14 blockade reduced THP-1 responses to LPS in a 
dose dependent manner with a 50µg/ml dose of M2E5 yielding a 90% blockade in CD14 
activity (Fig. S1). We therefore used the 50µg/ml dose of M2E5 to determine the effects of 
CD14 blockade on HP4A-NP uptake by primary hu-PBMC and found that blocking CD14 
had no effect on particle uptake compared to isotype control treated cells (Fig. 3E). We 
conclude that preferential uptake of HP4A-based NP by CD14+ monocytes is likely 
independent of CD14 function.
To determine if HP4A-based NPs induce cytotoxicity we treated whole buffy coat or 
enriched CD14+ monocytes (purity Fig. S2) with 100, 10 and 1 µg/ml doses of HP4A-based 
NP for 12 and 24 hours and monitored for cytotoxicity using two approaches. The first 
approach measured adenylate kinase release due to the loss of cell membrane integrity that 
coincides with cellular damage. We found no increase in adenylate kinase release from 
CD14 enriched cells treated with NPs compared to untreated cells (Fig. 4A), suggesting that 
the cell membrane remains uncompromised during NP treatment. Our second measure of 
cytotoxicity used an MTT-based assay to monitor cell survival following at 12 and 24 hours 
of NP treatment and found similar survival between untreated and NP treated cells (Fig. 4B). 
As a positive control for cell death we irradiated cells with UV light, which showed an 
expected decrease in MTT activity resulting from cytotoxicity (Fig. 4B). Based on these two 
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studies we conclude that PRINT fabricated HP4A hydrogel NPs do not induce cytotoxicity 
in primary human immune cells.
Cytokine induction and complement activation in response to HP4A-NP treatment
To determine if HP4A-NPs induce inflammatory responses from primary human immune 
cells we assessed supernatants of total hu-PBMC cultures treated with 10 µg/ml NP for 8 
hours using a Luminex based array. Most of the 30 cytokines tested were below the limit of 
detection (Fig. 5A). Of the cytokines within the detectable range only a modest increase 
(<40%) in MCP-1 (CCL2) reached statistical significance compared to untreated hu-PBMC 
(Fig. 5B). Based on the results of this broad cytokine analysis study we conclude that HP4A-
based NP do not elicit strong inflammatory cytokine responses from primary human 
immune cells.
We also tested whether HP4A-based NPs activate complement as other particle formulations 
have been shown to activate the complement pathway resulting in enhanced particle 
clearance and release of inflammatory mediators (36). One of the hallmarks of complement 
activation is cleavage of the complement C3α chain that results production of smaller 
fragments with opsonizing and inflammatory activity (47). We used a western blot approach 
to monitor cleavage of C3α in human plasma flowing incubation with PRINT HP4A-NPs 
compared to PBS alone or cobra venom factor (CVF) as a positive control for complement 
activation. Incubating CVF with human plasma results in loss of the full length C3α (115 
kDa) and accumulation of the 63 kDa and 40 kDa C3α’ cleavage products after 2 hour and 8 
hour treatments compared to PBS (Fig. 5C and D). In contrast, the full length C3α band 
remains intact when plasma is treated with HP4A and HP4A-PEG NP with no difference in 
accumulation of C3α’ products compared to PBS controls (Fig. 5C and D). From these data 
we conclude that PRINT HP4A-NPs are not significant activators of human complement or 
inflammatory cytokine production.
Uptake and immune responses to HP4A-NPs in humanized mice
The above data from ex-vivo cultured hu-PBMC suggest that HP4A-NPs are 
immunologically inert with respect to inflammatory cytokine production, cytotoxicity and 
complement activation. Whether these findings hold true in vivo would require unobtainable 
IRB approval for human studies. Thus, to assess how PRINT fabricated HP4A-based NPs 
interact with human immune cells in vivo we utilized a humanized mouse model 
(experimental design summarized in Fig. 6A). In this model, human CD34+ hematopoietic 
stem cells are isolated from fetal liver and injected into irradiated newborn immunodeficient 
NRG mice. Within 3–4 months the mouse immune system is reconstituted with human 
immune cells and all mice used in these studies had >50% chimerism. It is worth noting that 
our previous work identified major differences in the in vivo circulation times of 
nanoparticles depending on the mouse strain background, specifically the immunologic 
makeup of these conventional mice (19). Therefore, our efforts to use a humanized mouse 
model also sought to improve upon this shortcoming of conventional strains by modeling 
circulating human immune cells in vivo.
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Humanized mice were injected i.v. with 100µg of HP4A or HP4A-PEG NPs and analyzed 24 
hours later for particle uptake in the spleen and blood. Similarly to the ex-vivo cultured hu-
PBMC we were unable to detect NP uptake in the T, B and NK cell populations in the blood 
and spleen (Fig. 6B, and data not shown), and CD14+ monocytes were the only cell type 
with detectable NP compared to un-injected controls (Fig. 6B). There was also a significant 
difference in frequency of HP4A versus HP4A-PEG NPs uptake by splenic monocytes at 8 
hours (Fig. 6C). This in vivo finding that PEGylation of HP4A NP results in decreased 
uptake is consistent with our observations in the ex vivo hu-PBMC cultures. Lastly, we 
utilized Q-RT PCR to assess mRNA expression of inflammatory cytokines in the spleens of 
NP treated humanized mice compared to untreated controls. We did not detect any 
significant increases in TNF, IL6, or IL1B mRNA expression in mice treated with HP4A- or 
HP4A-PEG NPs compared to untreated controls (Fig. 6D). These in vivo data combined 
with our ex vivo primary hu-PBMC culture data indicate that PRINT fabricated HP4A-NPs 
are preferentially taken up by CD14+ monocytes and do not induce a robust inflammatory 
response by human immune cells. Together these studies suggest that PRINT hydrogel 
particles have the capacity for safe vaccine and drug delivery since they do not induce overt 
inflammatory responses or toxicity of human immune cells.
Discussion
The PRINT fabrication process yields NPs with defined shape and composition making it a 
leading candidate platform for diagnostic, therapeutic and preventative treatments in human 
disease. The hydrogel particles used in these studies were fabricated using PRINT and 
comprised of HP4A based PEG. Select formulations of PEG are F.D.A approved for human 
use and we sought to test how these particles interact with the human immune system. A 
variety of particulate molecules (alum, asbestos, silica, cholesterol crystals) can trigger 
inflammasome activation and release of IL-1β from LPS primed innate immune cells (48). 
The particulate nature of PRINT derived NPs raised concerns that they may have a similar 
capacity to activate the inflammasome, especially following LPS priming. We found that 
HP4A hydrogel particles were readily taken up by human THP-1 cells and primary hu-
PBMC without an inflammatory response. We are encouraged by the fact that IL-1β was not 
secreted in response to HP4A-NPs, even following LPS priming, suggesting that these 
particles do not induce or enhance inflammasome activation. The 30-Plex cytokine array of 
supernatant from ex vivo hu-PBMC cultures treated with NP showed only a modest increase 
in CCL2 secretion (~40%) and while statistically significant, may not be biologically 
relevant, especially with all other cytokines levels being unchanged compared to untreated 
controls. Additionally, our in vivo studies using a humanized mouse model also showed no 
differences in the mRNA level of hallmark inflammatory cytokines (TNF, IL6, IL1B) after 
NP treatment. Together, these studies support the notion that PRINT based HP4A-NPs are 
immunologically inert and do not cause cytotoxicity making them a feasible candidate 
platform for human therapeutics. In addition, given our previously published findings that 
the murine immune response to nanoparticles is strikingly dependent upon mouse strain 
background, our current study suggests that humanized mouse models may provide a 
tractable model for translational studies of nanomedicine as they recapitulate ex-vivo human 
PBMC studies well (19).
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Interestingly, the uptake of HP4A-NPs was exclusively detected in the CD14+ monocytic 
population of ex vivo cultured hu-PBMC and humanized mice, yet blockade of CD14 did not 
affect NP uptake and is therefore unlikely to be directly involved in NP recognition. Rather 
it is likely the inherent phagocytic properties of CD14+ monocytes that contribute to 
preferential NP uptake over other cell types. Modification of the NP surface by addition of 
short PEG chains reduced NP uptake by all cells tested, which is consistent with other 
studies suggesting that PEGylation is a viable means to reduce NP clearance and increase 
circulation time (49, 50). One hypothesis is that PEGylation reduces complement binding to 
the NP surface, thereby reducing opsonization and ingestion by phagocytic cells (16). 
Incubating hu-PBMC with NPs at 4°C, a temperature that should allow NP binding but not 
uptake, indicated that PEGylated NPs have significantly reduced capacity to bind monocytes 
compared to un-PEGylated NPs. Our failure to detect complement activation with PRINT 
fabricated HP4A-based NPs combined with that fact that our NP uptake studies were 
performed using heat inactivated serum, which is known to eliminate complement activity 
and reduce opsonization, suggests that our observed enhancement of un-PEGylated NP 
uptake at 4°C maybe complement independent (51, 52). This does not rule out the 
possibility that other heat resistant serum proteins bind the NP surface and enhance cellular 
binding and further studies using serum free conditions are needed to test this hypothesis. 
However, it is provocative to consider that PEGylation serves as a molecular lubricant that 
lowers the capacity for immune cells to grip the NP surface in a manner that is independent 
of serum-mediated opsonization.
Ultimately, the inability of PRINT fabricated HP4A-NPs to induce immune responses by 
primary human cells is advantageous for future design of human diagnostics and 
therapeutics. PRINT offers a modular platform in which various agents can be incorporated 
in a defined manner without concern of unwanted immune activation. The end goal of 
immune-engineering is to evoke potent and cell specific immune responses. Our studies 
indicate that PRINT fabricated HP4A-NPs are immunologically inert and passively target a 
major effector cell population of the human immune system, thereby providing an adjustable 
scaffold with the capacity to serve a variety of applications related to human health.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. HP4A-based PRINT NP Characterization
(A) Size, polydispersity index (PDI) and surface charge of HP4A and HP4A-PEG particles 
used in these studies. (B) SEM image of 80×320 nm HP4A-PEG rods.
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Figure 2. HP4A-based 80×320 nm rod uptake without inflammatory cytokine responses by 
THP-1 cells
(A) Dose dependent uptake of HP4A (solid black) and HP4A-PEG (dashed black) NP after 
24 hr. Grey fill, untreated cells. (B) ELISA for TNFα and IL-6 secretion 24 hours after NP 
treatment (20, 10, 1 µg/ml). Pos.cntrl, LPS treatment (100, 10, 1 ng/ml) for 8 hr. (C) ELISA 
for IL-1β secretion after 24hr NP treatment alone (20 µg/ml) or with LPS (10 ng/ml) added 
in the final 8 hours. Nigericin (20 µM) was added in the final 40 mins. as pos. cntrl for IL-1β 
secretion. (D) ELISA for TNFα secretion by THP-1 pre-treated with NP (10 µg/ml) for 16 
hr, followed by LPS (20 ng/ml) for 4hr. (E) ELISA for IL-1β secretion by THP-1 pre-treated 
with NP (10 µg/ml) for 16 hr, followed by LPS treatment (20 ng/ml) for 4hr and nigericin 
(20 µM) in the final 40 mins. Statistical analysis by 2-way ANOVA. N.D., not detected; n.s., 
not significant.
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Figure 3. HP4A-based 80×320 nm rod uptake by primary human PBMC
(A) Gating scheme used to analyze HP4A and HP4A-PEG NP uptake by T cells (CD3+), 
monocytes (CD14+), B cells (CD19+) and NK cells (CD56+) (B) Representative plot of HP 4 
A (solid black) and HP4A-PEG (dashed black) NP uptake by CD14 + cells after 4 and 8 hr 
treatment with NP (10 µg/ml). Grey fill, untreated cells. (C+D) Combined data from 4 
donors for frequency of CD14 + NP + cells (C) and mean fluorescence intensity (MFI) of NP 
signal within the CD14 + NP + gate (D). (E) Uptake of HP 4 A-NP (10 µg/ml) by CD14 + 
hu-PBMC at 8 hr in the presence of CD14 blocking antibody (50 µg/ml), solid line or 
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isotype control antibody (50 µg/ml), dashed line. Statistical analysis by 2-way ANOVA. 
*P<0.05, **P<0.01, ***P<0.001 Data in A-D are representative of two independent 
experiments using a total of 8 donors. Data in E are representative of two independent 
experiments using a total of 5 donors.
Robbins et al. Page 18













Figure 4. Undetectable toxicity following treatment of primary hu-PBMC with HP4A-based 
80×320 nm rods
(A) Luciferase based adenylate kinase assay for cell toxicity after treatment of primary 
human CD14 + cells with 100, 10 and 1 µg/ml HP4A or HP4A-PEG NP at 12 and 24 hr. 
100% lysis represents maximal toxicity signal. (B) MTT assay for cell survival after 
treatment of primary human peripheral blood buffy coat cells with 100, 10 and 1 µg/ml 
HP4A or HP4A-PEG NP at 12 and 24 hr. UV irradiated cells served as a positive control for 
cell death. Data in A are representative of two experiments using independently synthesized 
particles and cells from mixed donors. Data in B are combined results testing 6 independent 
batches of NP. RLU, relative light units; A.U., arbitrary units. Statistical Analysis by 1-way 
ANOVA with Tukey’s multiple comparisons test.
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Figure 5. Undetectable cytokine responses and complement activation following treatment of 
primary hu-PBMC with HP4A-based 80×320 nm rods
(A) List of cytokines below the limit of detection in hu-PBMC cultures treated with 10 
µg/ml HP4A or HP4A-PEG NP. (B) Multiplex cytokine ELISA data for untreated, HP4A or 
HP4A-PEG NP (10 µg/ml) treated PBMC after 8 hr. (C+D) Human complement C3α 
activation in plasma at 2 hr (C) and 8 hr (D) following treatment with HP4A and HP4A-PEG 
NP (10 µg/ml). Positive control; cobra venom factor (CVF) to induce C3α cleavage. 
Negative control PBS. Numbers indicate independent NP preparations (3 per particle type). 
Full length C3α (115 kDa). Expected C3α cleavage products (C3α’) 63 kDa and 40 kDa 
bands. The C3 β-chain (70 kDa) does not undergo cleavage and serves as a loading control. 
Data in A and B are combined from 4 independent PBMC donors. Statistical Analysis by 2-
way ANOVA. **P<0.01.
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Figure 6. HP4A-based 80×320 nm rod uptake and inflammatory cytokine responses using a 
humanized mouse model
(A) Schematic of humanized mouse model. CD34+ cells from hu fetal liver are injected into 
1–3 day old irradiated immunodeficient NRG (NOD.Rag1−/−Il2rg−/−) mice. 3–4 months 
post transplant the mice are injected with NP and human immune cells are analyzed for NP 
uptake. (B) Gating scheme used to analyze HP4A and HP4A-PEG (PEG) NP uptake by 
human T cells (anti-human CD45+ CD3+) or monocytes (anti-human CD45+CD14+). Gates 
for NP+ were set based on un-injected controls. (C) Frequency of NP+ cells in human 
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CD14+ gate from blood and spleen of humanized mice 24 hours after 100 µg NP injection. 
(D) mRNA expression level of human pro-inflammatory cytokines in spleen of untreated 
and NP treated humanized mice. n = 4 animals per treatment group. Statistical Analysis by 
2-way ANOVA. *P<0.05. Data are representative of two independent experiments.
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